Adverse reactions for the use of the monoclonal trastuzumab antibody in the treatment of patients with HER2 positive breast cancer
ABSTRACT Objective: Identify the main adverse reactions presented by patients with HER2 positive breast cancer from an outpatient clinic specialized in chemotherapy in the city of Caruaru-PE, after the use of Trastuzumab. Methods: The data were obtained through the analysis of the medical records of...
Saved in:
Main Authors: | Iago Dilion Lima Cavalcanti (Author), Analúcia Guedes Silveira Cabral (Author), Rosiel José dos Santos (Author) |
---|---|
Format: | Book |
Published: |
Facultad de Farmacia, Universidad de Granada.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022) -
Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
by: Sadeghi S, et al.
Published: (2014) -
Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
by: Azadeh Moghaddas, et al.
Published: (2016) -
Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
by: Steven Simoens, et al.
Published: (2021) -
Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
by: Anne Julienne Genuino, et al.
Published: (2019)